GAITHERSBURG, Md., Nov. 4, 2024
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company
advancing protein-based vaccines with its Matrix-M™ adjuvant, today
announced that Åsa Manelius, will join the Company in February 2025 as Managing Director of the Novavax
AB site in Uppsala, Sweden, the
primary manufacturing site for Matrix-M.
Ms. Manelius brings more than 25 years of experience leading
global operations and most recently worked at AstraZeneca in
Södertälje, leading the global supply chain for its Respiratory
& Immunology therapy area. Prior to this role, she served as
the General Manager of AstraZeneca's Sweden Biologic Center, a
global commercial and strategic launch site for biological
medicines.
"Åsa brings deep global operations knowledge to Novavax during a
critical time of transition for the Company," said
Rick Crowley, Chief Operations
Officer, Novavax. "As we focus on driving value via our proven
technology platform through partnerships and R&D, Åsa and our
AB site will be critical to ensuring robust supply of our
best-in-class Matrix-M™ adjuvant for both our pipeline and
potential partners."
"I'm excited to join Novavax and look forward to bringing my
deep expertise in development, CMC activities and manufacturing
operations to its adjuvant business," said Ms. Manelius. "There is
tremendous potential in Novavax's Matrix-M™ technology, and I look
forward to working with the team to create a true center of
excellence in Uppsala."
Ms. Manelius previously served as Managing Director at Biora AB
and in executive leadership roles at Pfizer Health AB. She
received an MSc/Chemical Engineering and a PhD in
Biotechnology/Biochemical Engineering from Lund University.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes
improved health by discovering, developing and commercializing
innovative vaccines to help protect against serious infectious
diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a
differentiated vaccine platform that combines a recombinant protein
approach, innovative nanoparticle technology and Novavax's patented
Matrix-M adjuvant to enhance the immune response. The Company's
portfolio includes its COVID-19 vaccine and its pipeline includes
COVID-19-Influenza Combination and stand-alone influenza vaccine
candidates. In addition, Novavax's adjuvant is included in the
University of Oxford and Serum
Institute of India's R21/Matrix-M
malaria vaccine. Please visit novavax.com and
LinkedIn for more information.
Forward-Looking Statements
Statements herein relating
to the future of Novavax, its operating plans and prospects, its
expectations regarding its clinical pipeline and research and
development efforts, are forward-looking statements. Novavax
cautions that these forward-looking statements are subject to
numerous risks and uncertainties that could cause actual results to
differ materially from those expressed or implied by such
statements. These risks and uncertainties include, without
limitation, challenges satisfying, alone or together with partners,
various safety, efficacy and product characterization requirements,
including those related to process qualification and assay
validation, necessary to satisfy applicable regulatory authorities;
difficulty obtaining scarce raw materials and supplies; resource
constraints, including human capital and manufacturing capacity, on
the ability of Novavax to pursue planned regulatory pathways;
challenges or delays in clinical trials; manufacturing,
distribution or export delays or challenges; Novavax's exclusive
dependence on Serum Institute of India Pvt. Ltd. for co-formulation
and filling and the impact of any delays or disruptions in their
operations on the delivery of customer orders; and those other risk
factors identified in the "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" sections of Novavax's Annual Report on Form 10-K for
the year ended December 31, 2023, and
subsequent Quarterly Reports on Form 10-Q, as filed with the
Securities and Exchange Commission (SEC). We caution investors not
to place considerable reliance on forward-looking statements
contained in this press release. You are encouraged to read our
filings with the SEC, available at www.sec.gov and
www.novavax.com, for a discussion of these and other risks
and uncertainties. The forward-looking statements in this press
release speak only as of the date of this document, and we
undertake no obligation to update or revise any of the statements.
Our business is subject to substantial risks and uncertainties,
including those referenced above. Investors, potential investors,
and others should give careful consideration to these risks and
uncertainties.
Contacts:
Investors
Luis Sanay, CFA
240-268-2022
ir@novavax.com
Media
Giovanna Chandler
240-720-7804
media@novavax.com
Photo -
https://mma.prnewswire.com/media/2547261/Novavax___Asa_Manelius.jpg
Logo -
https://mma.prnewswire.com/media/2344816/Novavax_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/asa-manelius-named-managing-director-of-novavax-ab-site-302294689.html